| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S13402-018-0409-1 |
| P698 | PubMed publication ID | 30259416 |
| P50 | author | Mona Pourjafar | Q88040056 |
| P2093 | author name string | Massoud Saidijam | |
| Fatemeh Karimi Dermani | |||
| Pouria Samadi | |||
| Sahar Saki | |||
| P2860 | cites work | Circulating microRNAs in plasma as early detection markers for breast cancer. | Q54294896 |
| The current state of breast cancer classification. | Q54481775 | ||
| [Role of let-7 in maintaining characteristics of breast cancer stem cells]. | Q54492842 | ||
| A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy | Q57579980 | ||
| Inside the professionals | Q59099495 | ||
| Phase II study of cisplatin and 5-fluorouracil in previously treated metastatic breast cancer: an Eastern Cooperative Oncology Group study (PA 185) | Q73272415 | ||
| Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results | Q73717915 | ||
| Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity | Q74079764 | ||
| Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor | Q84963968 | ||
| miR-892b Silencing Activates NF-κB and Promotes Aggressiveness in Breast Cancer | Q87043923 | ||
| Targeting a Long Noncoding RNA in Breast Cancer | Q87616370 | ||
| Zerumbone inhibits epithelial-mesenchymal transition and cancer stem cells properties by inhibiting the β-catenin pathway through miR-200c | Q89254595 | ||
| PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy | Q91327338 | ||
| Serum microRNAs are promising novel biomarkers | Q21144238 | ||
| MicroRNAs and their target gene networks in breast cancer | Q21195211 | ||
| Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells | Q21245767 | ||
| A multidrug resistance transporter from human MCF-7 breast cancer cells | Q22008574 | ||
| Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells | Q24300024 | ||
| MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer | Q24603354 | ||
| Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis | Q24607308 | ||
| MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1 | Q24648241 | ||
| Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model | Q24655262 | ||
| CRISPR/Cas9 therapeutics: a cure for cancer and other genetic diseases | Q26744172 | ||
| MicroRNA therapeutics: Discovering novel targets and developing specific therapy | Q26747644 | ||
| Injecting Hope--A Review of Breast Cancer Vaccines | Q26748882 | ||
| Roles, Functions, and Mechanisms of Long Non-coding RNAs in Cancer | Q26765422 | ||
| Targeting Oncogenic Mutant p53 for Cancer Therapy | Q26770856 | ||
| PI3K/Akt/mTOR inhibitors in breast cancer | Q26771394 | ||
| Breast cancer intrinsic subtype classification, clinical use and future trends | Q26773761 | ||
| MEK and PI3K inhibition in solid tumors: rationale and evidence to date | Q26775573 | ||
| Discovery and functional analysis of lncRNAs: Methodologies to investigate an uncharacterized transcriptome | Q26781885 | ||
| Targeting Breast Cancer Metastasis | Q26783925 | ||
| PARP inhibitors in the management of breast cancer: current data and future prospects | Q26798352 | ||
| Local and Systemic Therapies for Breast Cancer Patients: Reducing Short-term Symptoms with the Methods of Integrative Medicine | Q26800265 | ||
| Targeting the Bcl-2 family for cancer therapy | Q26866936 | ||
| CTLA-4 blockade in tumor models: an overview of preclinical and translational research | Q26992295 | ||
| Innate and adaptive immune cells in the tumor microenvironment | Q27008342 | ||
| Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models | Q27012618 | ||
| Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer | Q27022169 | ||
| miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents | Q27023295 | ||
| Small molecule compounds targeting the p53 pathway: are we finally making progress? | Q27027835 | ||
| The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing. | Q35183284 | ||
| Global cancer statistics, 2012 | Q27860501 | ||
| RAS is regulated by the let-7 microRNA family | Q27860522 | ||
| The functions of animal microRNAs | Q27860621 | ||
| MicroRNA gene expression deregulation in human breast cancer | Q27860690 | ||
| Silencing of microRNAs in vivo with 'antagomirs' | Q27860891 | ||
| Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells | Q27860960 | ||
| The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 | Q27861068 | ||
| MicroRNAs: genomics, biogenesis, mechanism, and function | Q27861070 | ||
| The role of lymphangiogenesis and angiogenesis in tumor metastasis | Q28067309 | ||
| Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review) | Q28080599 | ||
| MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential | Q28081081 | ||
| miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer | Q28115315 | ||
| Tumour invasion and metastasis initiated by microRNA-10b in breast cancer | Q28131829 | ||
| miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis | Q28236600 | ||
| let-7 microRNA functions as a potential growth suppressor in human colon cancer cells | Q28237683 | ||
| Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells | Q28256740 | ||
| let-7 regulates self renewal and tumorigenicity of breast cancer cells | Q28261263 | ||
| The heterochronic microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast cancer | Q28283868 | ||
| Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs | Q28537958 | ||
| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 | ||
| MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer | Q29547523 | ||
| MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer | Q29614237 | ||
| The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups | Q29614700 | ||
| CRISPR-Cas systems for editing, regulating and targeting genomes | Q29615781 | ||
| Cancer drug resistance: an evolving paradigm | Q29616694 | ||
| Endogenous human microRNAs that suppress breast cancer metastasis | Q29617352 | ||
| Breast cancer vaccines: a clinical reality or fairy tale? | Q30351838 | ||
| Breast tissue composition and susceptibility to breast cancer | Q30474496 | ||
| CD13 is a therapeutic target in human liver cancer stem cells | Q30496324 | ||
| The SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell Proliferation | Q30659086 | ||
| Retracted: miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells | Q31116416 | ||
| Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway | Q33305776 | ||
| MiR-155 promotes proliferation of human breast cancer MCF-7 cells through targeting tumor protein 53-induced nuclear protein 1 | Q33586516 | ||
| Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis | Q33591140 | ||
| Status of adjuvant endocrine therapy for breast cancer | Q33739138 | ||
| Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization | Q35204515 | ||
| Transgenic microRNA inhibition with spatiotemporal specificity in intact organisms. | Q35244937 | ||
| Apoptosis in cancer: from pathogenesis to treatment | Q35397889 | ||
| A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. | Q35503722 | ||
| Trends in breast biopsy pathology diagnoses among women undergoing mammography in the United States: a report from the Breast Cancer Surveillance Consortium | Q35567577 | ||
| Targeted therapies for ER+/HER2- metastatic breast cancer | Q35658860 | ||
| Various types and management of breast cancer: an overview | Q35664703 | ||
| Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine | Q35682712 | ||
| Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis | Q35782469 | ||
| LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer | Q35793883 | ||
| The Roles of MicroRNAs in Breast Cancer | Q35818407 | ||
| Downregulation of long noncoding RNA MALAT1 induces epithelial-to-mesenchymal transition via the PI3K-AKT pathway in breast cancer. | Q35853987 | ||
| Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials | Q35881780 | ||
| Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors | Q35906418 | ||
| Carboplatin in combination therapy for metastatic breast cancer | Q35914912 | ||
| The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. | Q35928749 | ||
| Continuous 5-fluorouracil in the treatment of breast cancer | Q36079497 | ||
| Small-molecule inhibitors of microrna miR-21 function | Q36192700 | ||
| Exosome removal as a therapeutic adjuvant in cancer | Q36232064 | ||
| Claudin-Low Breast Cancer; Clinical & Pathological Characteristics | Q36237815 | ||
| Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells. | Q36245418 | ||
| The silent treatment: siRNAs as small molecule drugs | Q36362370 | ||
| TGF-β upregulates miR-181a expression to promote breast cancer metastasis | Q36497263 | ||
| Systemic treatment in breast cancer: a primer for radiologists | Q36510679 | ||
| miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 | Q36525161 | ||
| The combinatorial activation of the PI3K and Ras/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence | Q36546319 | ||
| The roles of binding site arrangement and combinatorial targeting in microRNA repression of gene expression | Q36643186 | ||
| A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer | Q36759372 | ||
| Genetic heterogeneity of breast cancer metastasis may be related to miR-21 regulation of TIMP-3 in translation | Q37045230 | ||
| Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland | Q37051766 | ||
| MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells | Q37199087 | ||
| In vivo delivery of miRNAs for cancer therapy: challenges and strategies. | Q37228217 | ||
| NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma | Q37311506 | ||
| MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. | Q39102148 | ||
| MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). | Q39121337 | ||
| Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem-cell-like state | Q39176448 | ||
| miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells | Q39539625 | ||
| Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells | Q39587807 | ||
| Hereditary breast cancer: the era of new susceptibility genes | Q39657506 | ||
| A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo | Q40515986 | ||
| Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. | Q40811138 | ||
| Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. | Q40995818 | ||
| High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer | Q41073179 | ||
| Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector | Q41590056 | ||
| miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer | Q42493425 | ||
| Breast Cancer Vaccines: New Insights | Q42683276 | ||
| Targeted therapy: tailoring cancer treatment | Q42857529 | ||
| An elegant miRror: microRNAs in stem cells, developmental timing and cancer | Q43140992 | ||
| ABC transporters in cancer: more than just drug efflux pumps. | Q43193922 | ||
| Radiotherapy and survival in breast cancer | Q43495597 | ||
| Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer | Q47101500 | ||
| Breast cancer statistics, 2017, racial disparity in mortality by state. | Q47621558 | ||
| Cytoprotective effects of endothelin-1 on mesenchymal stem cells: an in vitro study. | Q47873444 | ||
| Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study | Q48032969 | ||
| The tumor suppressor PTEN is exported in exosomes and has phosphatase activity in recipient cells | Q48362692 | ||
| Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. | Q49975220 | ||
| Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial. | Q50904556 | ||
| Breast Cancer Immunotherapy. | Q51108833 | ||
| Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. | Q52009428 | ||
| Breast cancer metastasis: Putative therapeutic role of vascular cell adhesion molecule-1. | Q52094028 | ||
| A step-by-step microRNA guide to cancer development and metastasis. | Q52562647 | ||
| The versatile role of exosomes in cancer progression: diagnostic and therapeutic implications. | Q52581537 | ||
| Altered primary chromatin structures and their implications in cancer development. | Q52878923 | ||
| Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer. | Q52941950 | ||
| MicroRNA-124 regulates neuronal differentiation of mesenchymal stem cells by targeting Sp1 mRNA. | Q52978378 | ||
| Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. | Q53535574 | ||
| The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression | Q37315073 | ||
| mTOR inhibitors, a new era for metastatic luminal HER2-negative breast cancer? A systematic review and a meta-analysis of randomized trials | Q37317165 | ||
| Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer | Q37317395 | ||
| Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma | Q37406199 | ||
| Controlled delivery of antisense oligonucleotides: a brief review of current strategies. | Q37529859 | ||
| LncRNA H19 confers chemoresistance in ERα-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK. | Q37697180 | ||
| MicroRNAs--targeting and target prediction | Q37706854 | ||
| Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. | Q37950261 | ||
| miR-221/222: promising biomarkers for breast cancer | Q38093079 | ||
| Targeting long non-coding RNA to therapeutically upregulate gene expression | Q38110692 | ||
| Targeting long non-coding RNAs in cancers: progress and prospects | Q38113050 | ||
| Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis. | Q38140940 | ||
| Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines | Q38161367 | ||
| Recent insights into NF-κB signalling pathways and the link between inflammation and prostate cancer | Q38161514 | ||
| Targeting the BRCA1/2 tumor suppressors | Q38175472 | ||
| Efficacy of biological agents in metastatic triple-negative breast cancer | Q38188243 | ||
| Multitargeted antiangiogenic tyrosine kinase inhibitors combined to chemotherapy in metastatic breast cancer: a systematic review and meta-analysis | Q38190433 | ||
| Targeting PI3K/Akt/mTOR Signaling in Cancer | Q38208314 | ||
| Apoptosis and molecular targeting therapy in cancer | Q38228349 | ||
| Functional roles of long non-coding RNA in human breast cancer | Q38240022 | ||
| HER2-family signalling mechanisms, clinical implications and targeting in breast cancer | Q38301236 | ||
| MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). | Q38303663 | ||
| Peptide nucleic acids targeting miR-221 modulate p27Kip1 expression in breast cancer MDA-MB-231 cells | Q38321556 | ||
| Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer. | Q38563530 | ||
| A brief review on long noncoding RNAs: a new paradigm in breast cancer pathogenesis, diagnosis and therapy | Q38667920 | ||
| An immunogenic personal neoantigen vaccine for patients with melanoma | Q38692859 | ||
| Enhanced anti-tumor immunity against breast cancer induced by whole tumor cell vaccines genetically modified expressing α-Gal epitopes | Q38737738 | ||
| Targeting long non-coding RNA ASBEL with oligonucleotide antagonist for breast cancer therapy | Q38759411 | ||
| Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. | Q38769965 | ||
| Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy | Q38785707 | ||
| 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial | Q38953228 | ||
| LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. | Q38991643 | ||
| Cancer Statistics, 2017. | Q39038674 | ||
| MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways. | Q39095883 | ||
| microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma | Q33780259 | ||
| Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention | Q33820278 | ||
| The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer | Q33862290 | ||
| Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer | Q33862861 | ||
| Cancer targeted therapeutics: From molecules to drug delivery vehicles. | Q33887986 | ||
| Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. | Q33891809 | ||
| Functional significance of macrophage-derived exosomes in inflammation and pain | Q33932873 | ||
| miR-10b targets Tiam1: implications for Rac activation and carcinoma migration | Q33966873 | ||
| Biological subtypes of breast cancer: Prognostic and therapeutic implications | Q34023695 | ||
| Cysteine-rich 61-connective tissue growth factor-nephroblastoma-overexpressed 5 (CCN5)/Wnt-1-induced signaling protein-2 (WISP-2) regulates microRNA-10b via hypoxia-inducible factor-1α-TWIST signaling networks in human breast cancer cells | Q34054835 | ||
| MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene | Q34107532 | ||
| Targeting microRNAs in cancer: rationale, strategies and challenges | Q34141089 | ||
| MicroRNA sequence and expression analysis in breast tumors by deep sequencing | Q34185623 | ||
| The inhibitory role of Mir-29 in growth of breast cancer cells | Q34249355 | ||
| The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells | Q34315871 | ||
| p53 Family and Cellular Stress Responses in Cancer | Q34377287 | ||
| Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? | Q34455538 | ||
| Applications of the CRISPR-Cas9 system in cancer biology | Q34479139 | ||
| Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials | Q34486930 | ||
| Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement | Q34508652 | ||
| Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. | Q34539750 | ||
| Circulating microRNAs as specific biomarkers for breast cancer detection. | Q34542335 | ||
| CRISPR-mediated targeting of HER2 inhibits cell proliferation through a dominant negative mutation. | Q34544137 | ||
| New Immunotherapy Strategies in Breast Cancer | Q34549227 | ||
| MicroRNAs in Cancer Biology and Therapy: Current Status and Perspectives | Q34599354 | ||
| RNAi therapeutics: principles, prospects and challenges | Q34621268 | ||
| Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR-430. | Q34673364 | ||
| Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. | Q34798833 | ||
| MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis | Q34835189 | ||
| Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells | Q34899974 | ||
| Basal-like and triple-negative breast cancers: searching for positives among many negatives | Q35005793 | ||
| Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth | Q35029501 | ||
| Expression of two basic mRNA biomarkers in peripheral blood of patients with non-small cell lung cancer detected by real-time rt-PCR, individually and simultaneously. | Q35065394 | ||
| Concurrent chemoradiotherapy for locally advanced breast cancer-time for a new paradigm? | Q35072438 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 605-621 | |
| P577 | publication date | 2018-09-27 | |
| P1433 | published in | Cellular Oncology | Q2160503 |
| P1476 | title | Emerging ways to treat breast cancer: will promises be met? | |
| P478 | volume | 41 |
| Q89639970 | Diagnostic value of an automated breast volume scanner compared with a hand-held ultrasound: a meta-analysis |
| Q92412493 | Knockdown of long noncoding RNA TP73-AS1 suppresses the malignant progression of breast cancer cells in vitro through targeting miRNA-125a-3p/metadherin axis |
| Q58553890 | Long non-coding RNAs as monitoring tools and therapeutic targets in breast cancer |
| Q60919599 | The Interleukin-17 Family of Cytokines in Breast Cancer |
Search more.